Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) was the recipient of a significant growth in short interest in July. As of July 15th, there was short interest totalling 7,600 shares, a growth of 153.3% from the June 30th total of 3,000 shares. Approximately 1.3% of the company’s stock are sold short. Based on an average daily volume of 10,500 shares, the days-to-cover ratio is presently 0.7 days.

Alzamend Neuro Stock Down 2.1 %

Shares of Alzamend Neuro stock opened at $3.81 on Friday. Alzamend Neuro has a 52 week low of $3.27 and a 52 week high of $73.41. The firm’s 50 day moving average is $4.69 and its two-hundred day moving average is $7.29. The firm has a market capitalization of $3.05 million, a P/E ratio of -3.85 and a beta of 0.03.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Alzamend Neuro stock. Virtu Financial LLC acquired a new stake in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned approximately 0.38% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is currently owned by hedge funds and other institutional investors.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.